Japanese bio-venture starts development of COVID-19 peptide vaccine
TOKYO. KAZINFORM - A biotechnology venture in Japan said Thursday it started research and development of a peptide vaccine against the coronavirus and has completed a patent application filing, Kyodo reports.
The vaccine could be effective in controlling the virus infection and suppressing the severe progression of COVID-19, the respiratory disease caused by the novel coronavirus, OncoTherapy Science Inc. said in a statement.
Founded in 2001, OncoTherapy Science based in Kawasaki, Kanagawa Prefecture, has been working to develop cancer peptide vaccines and to provide a service for antigen-specific immune response analysis.